about
Insights into Phosphate Cooperativity and Influence of Substrate Modifications on Binding and Catalysis of Hexameric Purine Nucleoside PhosphorylasesBioretrosynthetic construction of a didanosine biosynthetic pathwayEvolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatmentModeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?Strategies for price reduction of HIV medicines under a monopoly situation in Brazil.Designing ARVs Patent Pool Up to Trade & Policy Evolutionary DynamicsFactors influencing global antiretroviral procurement prices.Design and directed evolution of a dideoxy purine nucleoside phosphorylase.On the margins of aid orthodoxy: the Brazil-Mozambique collaboration to produce essential medicines in Africa.Assessing directed evolution methods for the generation of biosynthetic enzymes with potential in drug biosynthesis.Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America.Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD.
P2860
Q27672664-F806693D-D65C-4C82-8158-08E449D346B5Q27682375-731E4A66-FC91-4DB5-9803-3FF78340C846Q28471623-496FD1B6-4A8C-4D82-B426-EA6B245E8E4AQ28476569-90102B9C-D00A-42C5-84E6-521645469E15Q30386525-D44FE831-7D29-4A0A-859C-31B44A490FBAQ30397036-535F861B-D1BE-48D8-B623-6A557379AC6EQ30892581-CCD8A9C0-2FCE-4D02-BC63-9DF99C7C5A4DQ33967613-CAF4657A-F33B-443D-BBAD-9D303D2E8B7AQ34309409-FD5F08AB-EF61-4B7C-B6B2-9D5C35ECAFE7Q35161643-2BDE19DE-F6C1-4B25-9A51-A99A6562138FQ35557326-2F73397F-ED8A-4A39-B3FB-A652D8708349Q35883654-DCCB9CFB-CC50-4DF2-B1AA-6E2AAF55DB0EQ36624327-5074A48B-28B2-40B4-9A02-34CA19266699Q38682631-B7E3D29A-2275-482D-BC05-EF48672344ACQ39124897-76A07E97-0C33-4559-84F5-9B292FDE05D2Q45408312-CCD0150B-DAE8-48FF-90FA-3298FF3D8953
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Examining the production costs of antiretroviral drugs.
@en
type
label
Examining the production costs of antiretroviral drugs.
@en
prefLabel
Examining the production costs of antiretroviral drugs.
@en
P2093
P1433
P1476
Examining the production costs of antiretroviral drugs.
@en
P2093
Ashwin Vasan
Eloan Pinheiro
Jean Marc Guimier
Jim Yong Kim
Joseph Perriens
P304
P356
10.1097/01.AIDS.0000242821.67001.65
P407
P577
2006-08-01T00:00:00Z